Role of NK cells in immunotherapy and virotherapy of solid tumors

Immunotherapy

Volumn 7, Issue 8, 2015, Pages 861-882

  Cantoni, Claudia ^a,b   Grauwet, Korneel ^c   Pietra, Gabriella ^a,d   Parodi, Monica ^a   Mingari, Maria Cristina ^a,d   De Maria, Andrea ^a,d   Favoreel, Herman ^c   Vitale, Massimo ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

immunotherapy; NK cells; solid tumor; tumor escape; tumor microenvironment; virotherapy

Indexed keywords

ONCOLYTIC VIRUS; PHOSPHOTRANSFERASE INHIBITOR;

CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; EXPERIMENTAL THERAPY; HUMAN; NATURAL KILLER CELL; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR MICROENVIRONMENT; BIOLOGICAL MODEL; CYTOTOXICITY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PHYSIOLOGY; PROCEDURES; VIROLOGY;

CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MODELS, IMMUNOLOGICAL; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TUMOR MICROENVIRONMENT;

EID: 84942114576     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.53     Document Type: Review

References (209)

1. Kärre K. How to recognize a foreign submarine. Immunol. Rev. 155, 5-9 (1997).
2. Moretta A, Vitale M, Bottino C et al. P58 molecules as putative receptors for majorhistocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J. Exp. Med. 178, 597-604 (1993).
3. Litwin V, Gumperz J, Parham P, Philips J, Lanier LL. NKB 1: A natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J. Exp. Med. 180, 537-543 (1994).
4. Sivori S, Vitale M, Morelli L et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J. Exp. Med. 186, 1129-1136 (1997).
5. Vivier E, Raulet DH, Moretta A et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44-49 (2011).
6. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin. Immunol. 18, 151-158 (2006).
7. Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 34, 182-191 (2013).
8. Hecht ML, Rosental B, Horlacher T et al. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J. Proteome Res. 8, 712-720 (2009).
9. Pogge von Strandmann E, Simhadri VR, von Tresckow B et al. A. Human leukocyte antigen-B-associated transcript is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27, 965-974 (2007).
10. Reiners KS, Topolar D, Henke A et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 121, 3658-3665 (2013).
11. Brandt CS, Baratin M, Yi EC et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer receptor NKp30 in humans. J. Exp. Med. 206, 1495-1503 (2009).
12. Schlecker E, Fiegler N, Arnold A et al. Metalloproteasemediated tumor cell shedding of B7.H6, the ligand of the natural killer activating receptor NKp30. Cancer Res. 74, 3429-3440 (2014).
13. Rosental B, Brusilovsky M, Hadad U et al. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J. Immunol. 187, 5693-5702 (2011).
14. Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debre P, Vieillard V. Identification of a cellular ligand for NKp44. Blood 122, 2935-2942 (2013).
15. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the activating NKG2D receptor. Annu. Rev. Immunol. 31, 413-441 (2013).
16. Ferrari de Andrade L, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol. Cell Biol. 92, 237-244 (2014).
17. Bottino C, Castriconi R, Pende D et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 198, 557-567 (2003).
18. Zhang Y, Wallace DL, de Lara CM et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 121, 258-265 (2007).
19. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83, 797-805 (1998).
20. Overwijk WW, Schluns KS. Functions ofC cytokines in immune homeostasis: current and potential clinical applications. Clin. Immunol. 132, 153-165 (2009).
21. Rodella L, Zamai L, Rezzani R et al. Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells. Br. J. Haematol. 115, 442-450 (2001).
22. Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214, 229-238 (2006).
23. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94(1), 333-339 (1999).
24. Locatelli F, Pende D, Mingari MC et al. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front. Immunol. 4 15 (2013).
25. Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin. Immunol. 26, 161-172 (2014).
26. Stojanovic A, Cerwenka A. Natural killer cells and solid tumors. J. Innate Immun. 3, 355-364 (2011).
27. Baginska J, Viry E, Paggetti J et al. The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity. Front. Immunol. 4, 490 (2013).
28. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells and tumor microenvironment on NKcell function. Eur. J. Immunol. 44, 1582-1592 (2014).
29. Shi FD, Ljunggren HG, La Cava A, Van Kaer, L. Organspecific features of natural killer cells. Nat. Rev. Immunol. 11, 658-671 (2011).
30. Montaldo E, Vacca P, Moretta L, Mingari MC. Development of human natural killer cells and other innate lymphoid cells. Semin. Immunol. 26, 107-113 (2014).
31. Eberl G, Di Santo JP, Vivier E. The brave new world of innate lymphoid cells. Nat. Immunol. 16, 1-5 (2015).
32. Sivori S, Olive D, Lopez-Botet M, Vitale M. NK receptors: tools for a polyvalent cell family. Front. Immunol. 5, 617 (2014).
33. Vacca P, Moretta L, Moretta A, Mingari MC. Origin, phenotype and function of human natural killer cells in pregnancy. Trends Immunol. 32, 517-523 (2011).
34. Bjorkstrom NK, Riese P, Heuts F et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116, 3853-3864 (2010).
35. Juelke K, Killig M, Luetke-Eversloh M et al. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 116, 1299-1307 (2010).
36. Lopez-Verges S, Milush JM, Pandey S et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116 3865-3874 (2010).
37. Moretta L. Dissecting CD56dim human NK cells. Blood 116, 3689-3691 (2010).
38. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc. Natl Acad. Sci. USA 108, 728-732 (2011).
39. Anfossi N, André P, Guia S et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25, 331-342 (2006).
40. Takeda K, Hayakawa Y, Smyth MJ et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7, 94-100 (2001).
41. Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 43, 362-372 (2006).
42. Tu TC, Brown NK, Kim TJ et al. CD160 is essential for NK-mediated IFN-g production. J. Exp. Med. 212, 415-429 (2015).
43. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol. Res. 2, 295-300 (2014).
44. Alvarez-Breckenridge CA, Yu J, Price R et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 18, 1827-1834 (2012).
45. Alvarez-Breckenridge CA, Yu J, Kaur B, Caligiuri MA, Chiocca EA. Deciphering the multifaceted relationship between oncolytic viruses and natural killer cells. Adv. Virol. 2012, 702839 (2012).
46. Balsamo M, Vermi W, Parodi M et al. Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor. Eur. J. Immunol. 42, 1833-1842 (2012).
47. Burke S, Lakshmikanth T, Colucci F, Carbone E. New views on natural killer cell-based immunotherapy for melanoma treatment. Trends Immunol. 31, 339-345 (2010).
48. Delahaye NF, Rusakiewicz S, Martins I et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat. Med. 17, 700-707 (2011).
49. Remark R, Alifano M, Cremer I et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin. Cancer Res. 19, 4079-4091 (2013).
50. Platonova S, Cherfils-Vicini J, Damotte D et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 71, 5412-5422 (2011).
51. Carrega P, Bonaccorsi I, Di Carlo E et al. CD56(bright) perforin(low) noncytotoxic NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J. Immunol. 192, 3805-3815 (2014).
52. Rusakiewicz S, Semeraro M, Sarabi M et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 73, 3499-3510 (2013).
53. Mamessier E, Sylvain A, Thibult ML et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J. Clin. Invest. 121, 3609-3622 (2011).
54. Ali TH, Pisanti S, Ciaglia E et al. Enrichment of CD56(dim)KIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat. Commun. 4(5), 539 (2014).
55. Halama N, Braun M, Kahlert C et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin. Cancer Res. 17, 678-689 (2011).
56. Balsamo M, Scordamaglia F, Pietra G et al. Melanomaassociated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl Acad. Sci. USA 106, 20847-20852 (2009).
57. Messaoudene M, Fregni G, Fourmentraux-Neves E et al. Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res. 74, 81-92 (2014).
58. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271 (2011).
59. Moretta A, Marcenaro E, Sivori S, Della Chiesa M, Vitale M, Moretta L. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol. 26, 668-675 (2005).
60. Bellora F, Castriconi R, Dondero A et al. TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells. Eur. J. Immunol. 44, 1814-1822 (2014).
61. Whiteside T. The tumor microenvironment and its role in tumor growth. Oncogene 27, 5904-5912 (2008).
62. Hoechst B, Voigtlaender T, Ormandy L et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50, 799-807 (2009).
63. Sprinzl MF, Reisinger F, Puschnik A et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 57, 2358-2368 (2013).
64. Kalinski P. Regulation of immune responses by prostaglandin E2. J. Immunol. 188, 21-28 (2012).
65. Castriconi R, Cantoni C, Della Chiesa M et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NKmediated killing of dendritic cells. Proc. Natl Acad. Sci. USA 100, 4120-4125 (2003).
66. Marcenaro E, Della Chiesa M, Bellora F et al. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J. Immunol. 17, 3992-3998 (2005).
67. Della Chiesa M, Carlomagno S, Frumento G et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function. Blood 108, 4118-4125 (2006).
68. Ghiringhelli F, Menard C, Terme M et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 202, 1075-1085 (2005).
69. Sitrin J, Ring A, Garcia KC, Benoist C, Mathis D. Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J. Exp. Med. 210, 1153-1165 (2013).
70. Li T, Yang Y, Hua X. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett. 318, 154-161 (2012).
71. Li T, Yi S, Liu W et al. Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity. Med. Oncol. 30, 663 (2013).
72. Pietra G, Manzini C, Rivara S et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 72, 1407-1415 (2012).
73. Krockenberger M, Dombrowski Y, Weidler C et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by downregulating NKG2D. J. Immunol. 180, 7338-7348 (2008).
74. Gubbels JA, Felder M, Horibata S et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer 9, 11 (2010).
75. Castriconi R, Dondero A, Bellora F et al. Neuroblastomaderived TGF-b1 modulates the chemokine receptor repertoire of human resting NK cells. J. Immunol. 190, 5321-5328 (2013).
76. Schlecker E, Fiegler N, Arnold A et al. Metalloproteasemediated tumor cell shedding of B7.H6, the ligand of the natural killer activating receptor NKp30. Cancer Res. 74, 3429-3440 (2014).
77. Balsamo M, Manzini C, Pietra G et al. Hypoxia downregulates the expression of activating receptors involved in NK-cellmediated target cell killing without affecting ADCC. Eur. J. Immunol. 43, 2756-2764 (2013).
78. Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O. Tumor immunoediting by NKp46. J. Immunol. 184, 5637-5644 (2010).
79. Lankry D, Rovis TL, Jonjic S, Mandelboim O. The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells. Eur. J. Immunol. 43, 2151-2161 (2013).
80. Ames E, Murphy WJ. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol. Immunother. 63, 21-28 (2014).
81. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9, 486-494 (2008).
82. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
83. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J. Exp. Med. 209, 2351-2365 (2012).
84. Vacchelli E, Galluzzi L, Eggermont A et al. Trial Watch: immunostimulatory cytokines. Oncoimmunology 1, 493-506 (2012).
85. Tarhini AA, Millward M, Mainwaring P et al. A Phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115, 859-868 (2009).
86. Conlon KC, Lugli E, Welles HC et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74-82 (2015).
87. Ardolino M, Azimi CS, Iannello A et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J. Clin. Invest. 124, 4781-4794 (2014).
88. Romagné F, André P, Spee P et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 114, 2667-2677 (2009).
89. Kohrt HE, Thielens A, Marabelle A et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123, 678-686 (2014).
90. Pahl JH, Rusian EN, Buddingh EP et al. Anti-EGFR antibody Cetuximab enhances the cytolytic activity of natural killer cells towards osteosarcoma. Clin. Cancer Res. 18, 432-441 (2012).
91. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat. Rev. Cancer 12, 278-287 (2012).
92. Krieg S, Ullrich E. Novel immune modulators in hematology: impact on NK cells. Front. Immunol. 3, 388 (2013).
93. Benson DM Jr, Bakan CE, Zhang S et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118, 6387-6391 (2011).
94. Law TM, Motzer RJ, Mazumdar M et al. Phase III randomized trial of interleukin-2 with or without lymphokineactivated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824-832 (1995).
95. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17, 6287-6297 (2011).
96. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057 (2005).
97. Geller MA, Cooley S, Judson PL et al. A Phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13, 98-107 (2011).
98. Iliopoulou EG, Kountourakis P, Karamouzis MV et al. A Phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol. Immunother. 59, 1781-1789 (2010).
99. Nishida S, Levi DM, Tzakis AG. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma. Curr. Opin. Organ Transplant 18, 690-694 (2013).
100. Tanimine N, Ohdan H. Impact of multipicity of functional KIR-HLA compound genotypes on hepatocellular carcinoma. Oncoimmunology 4(1), e983765 (2015).
101. Villegas FR, Coca S, Villarrubia VG et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35, 23-28 (2002).
102. Coca S, Perez-Piqueras J, Martinez D et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79, 2320-2328 (1997).
103. Ishigami S, Natsugoe S, Tokuda K et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88, 577-583 (2000).
104. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104, 3664-3671 (2004).
105. Lopez-Verges S, Milush JM, Schwartz BS et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA 108, 14725-14732 (2011).
106. Beziat V, Liu LL, Malmberg JA et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 121, 2678-2688 (2013).
107. Della Chiesa M, Falco M, Muccio L, Bertaina A, Locatelli F, Moretta A. Impact of HCMV infection on NK cell development and function after HSCT. Front. Immunol. 4 458 (2013).
108. Wennerberg E, Kremer V, Childs R, Lundqvist A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol. Immunother. 64, 225-235 (2015).
109. Oberoi P, Wels WS. Arming NK cells with enhanced antitumor activity: CARs and beyond. Oncoimmunology (8), e25220 (2013).
110. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
111. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
112. Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
113. Glienke W, Esser R, Priesner C et al. Advantages and applications of CAR-expressing natural killer cells. Front. Pharmacol. 6, 21 (2015).
114. Sahm C, Schonfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol. Immunother. 61, 1451-1461 (2012).
115. Woller N, Gürlevik E, Ureche C-I, Schumacher A, Kühnel F. Oncolytic viruses as anticancer vaccines. Front. Oncol. 4 188 (2014).
116. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol. Res. 2(4), 295-300 (2014).
117. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7, 141-148 (2007).
118. Xia ZJ, Chang JH, Zhang L et al. [Phase III randomized clinical trial of intratumoral injection of E1B genedeleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Ai Zheng 23, 1666-1670 (2004).
119. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J. Natl Cancer Inst. 98, 298-300 (2006).
120. Pol J, Bloy N, Obrist F et al. Trial Watch: oncolytic viruses for cancer therapy. Oncoimmunology 3, e28694 (2014).
121. Burke JM, Lamm DL, Meng MW et al. A first in human Phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J. Urol. 188, 391-2397 (2012).
122. Dingli D, Peng KW, Harvey ME et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103, 1641-1646 (2004).
123. Geletneky K, Huesing J, Rommelaere JR et al. Phase I/ IIa study of intratumoral/intracerebral or intravenous/ intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 12, 99 (2012).
124. Mansour M, Palese P, Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J. Virol. 85, 6015-6023 (2011).
125. Galanis E, Markovic SN, Suman VJ et al. Phase II trial of intravenous administration of Reolysin (Reovirus Serotupe-3-dearing Strain) in patients with metastatic melanoma. Mol. Ther. 10, 1998-2003 (2012).
126. Kuhn I, Harden P, Bauzon M et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE 3, e2409 (2008).
127. MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoit neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J. Gen. Virol. 72, 631-639 (1991).
128. Harland J, Papanastassiou V, Brown SM. HSV-1716 persistence in primary human glioma cells in vitro. Gene Ther. 9, 1194-1198 (2002).
129. Papanastassiou V, Rampling R, Fraser M et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV-1716 following intratumoral injection into human malignant glioma: A proof of principle study. Gene Ther. 9, 398-406 (2002).
130. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW. Proc. Natl Acad. Sci. USA 97, 6097-6101 (2000).
131. Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5-mutants of herpes simplex virus 1. Proc. Natl Acad. Sci. USA 92, 10516-10520 (1995).
132. Randazzo BP, Kucharczuk JC, Litzky LA et al. Herpes simplex 1716-an ICP 34.5 mutant-is severely replication restricted in human skin xenografts in vivo. Virology 223, 392-395 (1996).
133. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 65, 2832-2839 (2005).
134. Ning J, Wakimoto H. Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy. Front. Microbiol. 5, 303 (2014).
135. Woiton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev. 21, 127-134 (2010).
136. Yacoov B, Lazar I, Tayeb S et al. Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity. J. Gen. Virol. 93, 1664-1672 (2012).
137. Markert JM, Liechty PG, Wang W et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and posttumor resection for recurrent GBM. Mol. Ther. 17, 199-207 (2009).
138. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol. Ther. 18, 1275-1283 (2010).
139. Rodriguez-Garcia A, Giménez-Alejandre M, Rojas JJ et al. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin. Cancer Res. 21, 1406-1418 (2015).
140. Lopez C, Kirkpatrick D, Read SE et al. Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus infections. J. Infect. Dis. 147, 1030-1035 (1983).
141. Orange JS. Natural killer cell deficiency. J. Allergy Clin. Immunol. 132, 515-525 (2013).
142. Petitdemange C, Becquart P, Wauquier N et al. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog. 7, e1002268 (2011).
143. Marras F, Bozzano F, Ascierto ML, De Maria A. Baseline and dynamic expression of activating NK cell receptors in the control of chronic viral infections: the paradigm of HIV-1 and HCV. Front. Immunol. 5, 305, (2014).
144. Mandelboim O, Lieberman N, Lev M et al. Recognition of hemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409, 1055-1060 (2001).
145. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur. J. Immunol. 31, 2680-2689 (2001).
146. Hershkovitz O, Rosental B, Rosenberg LA et al. NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J. Immunol. 183, 2610-2621 (2009).
147. Chisholm SE, Reyburn HT. Recognition of vaccinia virusinfected cells by human natural killer cells depends on natural cytotoxicity receptors. J. Virol. 80, 2225-2233 (2006).
148. Cerboni C, Fionda C, Soriani A et al. The DNA damage response: A common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected and cancer cells. Front. Immunol. 4, 508 (2014).
149. Arnon TI, Achdout H, Lieberman N et al. The mechanosms controlling the recognition of tumor-and virus-infected cells by NKp46. Blood 103, 664-672 (2004).
150. Jarahian M, Watzl C, Fournier P et al. Activation of natural killer cells by Newcastle disease virus hemagglutininneuraminidase. J. Virol. 83, 8108-8121 (2009).
151. Jarahian M, Fiedler M, Cohnen A et al. Modulation of NKp30-and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog. 7, e1002195 (2011).
152. Fogli M, Costa P, Murdaca G et al. Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur. J. Immunol. 34, 2313-2321 (2004).
153. De Maria A, Fogli M, Costa P et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur. J. Immunol. 33, 2410-2418 (2003).
154. Mavilio D, Lombardo G, Kinter A et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J. Exp. Med. 203, 2339-2350 (2006).
155. De Maria A, Mavilio D, Costa P, Dignetti P, Fogli M, Mingari MC. Multiple HLA-class I-specific inhibitory NK receptor expression and IL-4/IL-5 production by CD8+ T-cell clones in HIV-1 infection. Immunol. Lett. 72, 179-182 (2000).
156. Ward J, Bonaparte M, Sacks J et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. 110, 1207-1214 (2007).
157. Matusali G, Tchidjou HK, Pontrelli G et al. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. FASEB J. 27, 2440-2450 (2013).
158. Cerboni C, Neri F, Casartelli N et al. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J. Gen. Virol. 88, 242-250 (2007).
159. Lisnic VJ, Krmpotic A, Jonjic S. Modulation of natural killer cell activity by viruses. Curr. Opin. Microbiol. 13, 530-539 (2010).
160. Jost S, Altfeld M. Evasion from NK cell-mediated immune responses by HIV-1. Microbes Infect. 14, 904-915 (2012).
161. Grauwet K, Cantoni C, Parodi M et al. Modulation of CD112 by the alphaherpesvirus gD protein suppresses DNAM-1-dependent NK cell-mediated lysis of infected cells. Proc. Natl Acad. Sci. USA 111, 16118-16123 (2014).
162. Crotta S, Brazzoli M, Piccioli D, Valiante NM, Wack A. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J. Hepatology 52, 183-190 (2010).
163. Crotta S, Stilla A, Wack A et al. Inhibition of natural killer cells through Engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 195, 35-42 (2002).
164. De Maria A, Fogli M, Mazza S et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic patients. Eur. J. Immunol. 37, 445-455 (2007).
165. Yoon JC, Shiina M, Ahlenstiel G, Rehemann B. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 49, 12-21 (2009).
166. Chisholm SE, Howard K, Gomez MV, Reyburn HT. Expression of ICP0 is sufficient totrigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors. J. Infect. Dis. 195, 1160-1168 (2007).
167. Schepis D, D'Amato M, Studah M, Bergstrom T, Karre K, Berg L. Herpes simplex virus infection downmodulates NKG2D ligand expression. Scand. J. Immunol. 69, 429-436 (2009).
168. Costa P, Sivori S, Bozzano F et al. IFN-alpha-mediated increase in cytolytic activity of maturing NK cell upon exposure to HSV-infected myelomonocytes. Eur. J. Immunol. 39, 147-158 (2009).
169. Arnon TI, Achdout H, Levi O et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat. Immunol. 6, 515-523 (2005).
170. Magri G, Muntasell A, Romo N et al. NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood 117, 848-856 (2011).
171. Madrid AS, Ganem D. Kaposi's sarcoma-associated herpesvirus ORF54/dUTPase downregulates a ligand for the NK activating receptor NKp44. J. Virol. 86, 8693-8701 (2012).
172. Dupuy S, Lambert M, Zucman D et al. Human herpesvirus (HVV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcoma. PLoS Pathog. 8, e1002486 (2012).
173. Holder KA, Stapleton SN, Gallant ME, Russell RS, Grant MD. Hepatitis C virus-infected cells downregualte NKp30 and inhibit ex vivo NK cell functions. J. Immunol. 191, 3308-3318 (2013).
174. Amadei B, Urbani S, Cazaly A et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 138, 1536-1545 (2010).
175. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology 52, 1581-1589 (2010).
176. Bhat R, Rommelaere J. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells. BMC Cancer 13(367) (2013).
177. Vieillard V, Strominger K, Debrè P. NK cytotoxicity against CD4+ T cells during HIV-1 infection: A gp41 peptide induces the expression of an NKp44 ligand. Proc. Natl Acad. Sci. USA 102, 10981-10986 (2005).
178. Fausther-Bovendo H, Sol-Foulon N, Candotti D et al. HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD4 T cells. AIDS 23, 1077-1087 (2009).
179. Richard J, Sindhu S, Pham TNQ, Belzile J-P, Cohen A. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood 115, 1354-1363 (2010).
180. Ogbomo H, Zemp FJ, Lun X et al. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. PLoS ONE 8(6), e66825 (2013).
181. Muntasell A. Vilches C. Angulo A. López-Botet M. Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: A different perspective of the host-pathogen interaction. Eur. J. Immunology 43, 1133 (2013).
182. Bjorkstrom NK, Lindgren T, Stoltz M et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J. Exp. Med. 208, 13-21 (2011).
183. Khakoo S, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305, 872-874 (2004).
184. Werner JM, Heller T, Gordon AM et al. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection. Hepatology 58, 1621-1631 (2013).
185. Bozzano F, Picciotto A, Costa P et al. Activating NK cell receptor expression/function (NKp30,NKp46,DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur. J. Immunol. 41, 2905-2914 (2011).
186. Martin MP, Gao X, Lee J-H et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31, 429-434 (2002).
187. Marras F, Nicco E, Bozzano F et al. Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. Proc. Natl Acad. Sci. USA 10, 11970-11975 (2013).
188. Rintoul JL, Lemay CG, Tai L-H et al. ORFV: A novel oncolytic and immune stimulating parapoxvirus therapeutic. Mol. Ther. J. Am. Soc. Gene Ther. 20(6), 1148-1157 (2012).
189. Granot T, Venticinque L, Tseng J-C, Meruelo D. Activation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectors. PLoS ONE 6(6), e20598 (2011).
190. Zhang J, Tai L-H, Ilkow CS et al. Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Mol. Ther. J. Am. Soc. Gene Ther. 22(7), 1320-1332 (2014).
191. Dempe S, Lavie M, Struyf S et al. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol. Immunother. 61(11), 2113-2123 (2012).
192. Kottke T, Diaz RM, Kaluza K et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol. Ther. J. Am. Soc. Gene Ther. 16(12), 1910-1918 (2008).
193. Kottke T, Galivo F, Wongthida P et al. Treg depletionenhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol. Ther. J. Am. Soc. Gene Ther. 16(7), 1217-1226 (2008).
194. Freytag SO, Barton KN, Zhang Y. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther. 20(12), 1131-1139 (2013).
195. Choi I-K, Lee J-S, Zhang S-N et al. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12R2 or IL-18R. Gene Ther. 18(9), 898-909 (2011).
196. Cerullo V, Diaconu I, Romano V et al. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol. Ther. J. Am. Soc. Gene Ther. 20(11), 2076-2086 (2012).
197. John LB, Howland LJ, Flynn JK et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res. 72(7), 1651-1660 (2012).
198. Lemay CG, Rintoul JL, Kus A et al. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol. Ther. J. Am. Soc. Gene Ther. 20(9), 1791-1799 (2012).
199. Prestwich RJ, Errington F, Steele LP et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J. Immunol. 183(7), 4312-4321 (2009).
200. Komaru A, Ueda Y, Furuya A et al. Sustained and NK/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus. J. Immunol. 183(7), 4211-4219 (2009).
201. Kaufmann JK, Chiocca EA. Glioma virus therapies between bench and bedside. Neuro. Oncol. 16(3), 334-351 (2014).
202. Altomonte J, Wu L, Chen L et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vectormediated suppression of inflammatory responses in vivo. Mol. Ther. J. Am. Soc. Gene Ther. 16(1), 146-153 (2008).
203. Tomasec P, Wang ECY, Davison AJ et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat. Immunol. 6(2), 181-188 (2005).
204. Prod'homme V, Sugrue DM, Stanton RJ et al. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. J. Gen. Virol. 91(Pt 8), 2034-2039 (2010).
205. Altomonte J, Wu L, Meseck M et al. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther. 16(3), 266-278 (2009).
206. Alvarez-Breckenridge CA, Yu J, Price R et al. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J. Virol. 86(8), 4566-4577 (2012).
207. Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev. Microbiol. 12, 23-34 (2014).
208. Granot T, Meruelo D. The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan. Cancer Gene Ther. 19(8), 588-591 (2012).
209. Willmon C, Diaz RM, Wongthida P et al. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol. Ther. J. Am. Soc. Gene Ther. 19(1), 140-149 (2011).